Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Global Medical Radiation Detection Market Set to Grow from $1.26B in 2024 to…
Browse in-depth TOC on "Medical Radiation Detection Market" Browse in-depth TOC on "Medical Radiation Detection Market" 588 - Tables 48 - Figures 424 - Pages The medical radiation detection, monitoring & safety market has been segmented into Personal dosimeters, Area Process Monitors, Environment Radiation Monitors, Surface Contamination Monitors, Radioactive Material Monitors, and Other Radiation Detection and Monitoring Products categories on the basis of product...
PR Newswire
20/09/2024
Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new…
European Commission grants conditional marketing authorization for Iqirvo ®(elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows positive CHMP opinion based on ELATIVE phase III trial data, which demonstrated significant efficacy over placebo and was well-tolerated with an acceptable safety profile This new European approval reinforces Ipsen's commitment to advancing medical innovations to treat people...
Nasdaq GlobeNewswire
20/09/2024
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Bagsværd, Denmark, 20 September 2024– Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [ Link ].The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant compared to placebo on body weight after 16 weeks in 243...
Nasdaq GlobeNewswire
20/09/2024
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted…
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine generates a substantially improved response against multiple circulating Omicron JN.1 sublineages as did the Omicron JN.1-adapted COVID-19 vaccine authorized by the European Commission in July 2024Doses will be ready to ship to applicable European Union member states as...
Nasdaq GlobeNewswire
20/09/2024
Press Release: Dupixent recommended for EU approval by the CHMP to treat…
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion of children on Dupixent achieved histological remission, compared to placebo, consistent with improvements seen in adults and adolescentsIf approved, Dupixent would be the first and only medicine in the EU indicated for EoE in this age groupParis and Tarrytown, NY, September 20, 2024...
Nasdaq GlobeNewswire
20/09/2024
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of…
Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 studyData presented at ECTRIMS show that tolebrutinib, a brain-penetrant BTK inhibitor, addresses disability accumulation that occurs independently from relapse activityGlobal regulatory submissions will begin in H2 2024Paris, September 20, 2024.Positive results from the HERCULES phase 3 study in people with non-relapsing...
Nasdaq GlobeNewswire
20/09/2024
UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis…
"Despite the current developments of new treatments in AD, there is a clear need for safe and efficacious oral treatments. Impact on patients' experience of itch and pain along with lesional improvements are key to determine the relevance of a treatment", says Prof. Dr. Eric Simpson. "I am excited to present the results from the Phase 2b ADESOS study at the EADV Congress 2024, showing that orismilast offers the promise as a novel treatment option in AD with early impact on…
PR Newswire
20/09/2024
Funeral Services Market to Reach $88.6 Billion, Globally, by 2033 at 3.8% CAGR…
Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A06825 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A06825 Prime determinants of growth Rise in geriatric population, which is prone to critical illnesses, is a major factor that boosts the growth of the market. Cultural shifts toward personalized and meaningful ceremonies drive demand for customized funeral services, catering to...
PR Newswire
20/09/2024
213,285 Orion Corporation A shares converted into B shares
ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 20 SEPTEMBER 2024 at 9.30 EEST 213,285 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 213,285 A shares have been converted into 213,285 B shares. The conversion has been entered into the Trade Register on 20 September 2024.The total number of shares in Orion Corporation is...
Nasdaq GlobeNewswire
20/09/2024
Bioretec's Shareholders' Nomination Board appointed
The Shareholders' Nomination Board is responsible for preparing and presenting to the AGM a proposal on the members of the Board of Directors as well as proposals on the remuneration and number of members of the Board of Directors. The Shareholders' Nomination Board will submit its proposals for the 2025 AGM to the Board of Directors by 31 January 2025. The Shareholders' Nomination Board is responsible for preparing and presenting to the AGM a proposal on the members of the Board...
PR Newswire
20/09/2024
Financière de Tubize - Transparency notification
Publication concerning a transparency notification(article 14, first paragraph of the law of 2 May 2007 concerning the publication of significant participating interests)Press release - Regulated informationBrussels, 20 September 2024 - 8:00 CET Summary of the notificationFinancière de Tubize has received a transparency notification dated 17 September 2024, as a result of which, on 1 August 2024, Barnfin SA acquired 11,744 shares from Jonkheer van Rijckevorsel, which consequently...
Nasdaq GlobeNewswire
20/09/2024
Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies |…
Key Takeaways from the Mantle Cell Lymphoma Pipeline Report Key Takeaways from the Mantle Cell Lymphoma Pipeline Report Request a sample and discover the recent advances in mantle cell lymphoma treatment drugs @ Mantle Cell Lymphoma Pipeline Report The mantle cell lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage mantle cell lymphoma drugs, inactive and dormant assets, a comprehensive assessment of...
PR Newswire
19/09/2024
Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to…
Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities acted as joint book-running managers for the offering.Registration statements relating to the shares sold in the offering have been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on September 12, 2024. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street,...
Nasdaq GlobeNewswire
19/09/2024
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate…
Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen's Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC)€59.0 million in revenues, including the €48.7 million milestone invoiced in June 2024 Positive opinion from the European Medicines Agency Committee in July 2024, with final decision on marketing authorization for...
Nasdaq GlobeNewswire
19/09/2024
Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in…
PR Newswire
19/09/2024
Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for…
Wegovy ®recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical functionWegovy ®(semaglutide 2.4 mg) is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise function in people with obesity-related heart failure with preserved ejection fraction (HFpEF).The positive opinion is based on results...
Nasdaq GlobeNewswire
19/09/2024
CARBIOS and SLEEVER® partner up to co-develop and bring to market first Home…
Clermont-Ferrand and Morangis (France), Thursday 19 September 2024 (6pm CEST). CARBIOS,(Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, andSLEEVER®, a French family-owned group International SME and innovative leader in shrinksleeve label technology, today announced the signing of an exclusive, long-term contract to jointly develop Home Compost biodegradable mono-oriented...
Nasdaq GlobeNewswire
19/09/2024
Automatic Mower Market Poised for Strong Growth with a Projected Value of $5.8…
Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=296147 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=296147 202 - Pages126 – Tables37 – Figures Scope Of The Report Automatic Mower Market Overview 1.Market Growth and SizeThe global automatic mower market has been experiencing substantial growth, valued at approximately$3.5 billionin 2024. The market is projected to expand...
PR Newswire
19/09/2024
Office Furniture Market to Reach $117.4 Billion, Globally, by 2033 at 7.1% CAGR…
Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A06417 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A06417 Prime Determinants of Growth The prime determinants of growth in the office furniture market include increase in corporate expansions and the need for modern office spaces, which drive the demand for new and upgraded furniture. The shift towards remote and hybrid work models...
PR Newswire
19/09/2024
Autoradiography Films Market to Reach $174.9 Million, Globally, by 2033 at 3%…
Prime determinants of growth Prime determinants of growth Increase in prevalence of chronic diseases, surge in technological advancements, and rise in R&D activities in the healthcare sector are the major factors that drive the growth of the autoradiography films market growth. However, high initial costs and maintenance expenses associated with autoradiography equipment poses a significant restraint on the growth of the autoradiography films market. Moreover, growth opportunities...
PR Newswire
19/09/2024
Physiotherapy Equipment Market is expected to generate a revenue of USD 14.88…
As demand for advanced rehabilitation solutions rises due to increasing global healthcare spending, growing prevalence of chronic diseases, and the aging population, the physiotherapy equipment sector is experiencing substantial growth. Our new report provides a strategic roadmap for stakeholders to navigate this evolving landscape, equipping them with actionable intelligence to maintain a competitive edge. As demand for advanced rehabilitation solutions rises due to increasing global...
PR Newswire
19/09/2024
Rejuveron Life Sciences AG Rebrands as Centenara Labs AG and Provides Latest…
Shareholders approve name change and rebranding to Centenara Labs AG (“Centenara”) Rebrand positions business for strategic initiatives designed to support development of therapies for regenerative medicine and age-related disordersCompany also reports encouraging preliminary clinical results on novel blindness treatment, EA-2353 for Retinitis Pigmentosa SCHLIEREN, Switzerland, Sept.19, 2024(GLOBE NEWSWIRE) -- Centenara Labs AG (“ Centenara ” or the “ Company ”) (formerly...
Nasdaq GlobeNewswire
19/09/2024
ZINZINO AB (PUBL): Share subscription due to directed set-off issues
Through the directed issues, the number of B shares in the company increases by a total of 257 270 to a total of 29 451 599. The total number of shares after the increase amounts to 34,564,991. The dilution amounts to 0.7 percent, calculated on the number of total shares in the company upon completion of the directed issues. Zinzino's share capital increases through the directed issues by SEK 25,727 to SEK 3,456,499.10. Through the directed issues, the number of B shares in the company...
PR Newswire
19/09/2024
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents the second EMA approval of an MVA-BN-based vaccine for a younger populationCOPENHAGEN, Denmark, September 19, 2024– Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II variation for IMVANEX ®(MVA-BN) smallpox and mpox...
Nasdaq GlobeNewswire
19/09/2024
Altri Comunicati